loading page

Tocilizumab for treating severe COVID-19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir and favipiravir: case series
  • +9
  • Manoon Surabotsophon,
  • Yingyot Klai-On,
  • Vipa Thanachartwet,
  • Sirote Khunapornphairote,
  • Supat Chamnanchanunt,
  • Theerapat Racharak,
  • Wannada Laisuan,
  • Duangjai Sahassananda,
  • Samlee Hapunna,
  • Somjit Jinapuk,
  • Suthee Leelasetakul,
  • Varunee Desakorn
Manoon Surabotsophon
Ramkhamhaeng Hospital plc
Author Profile
Yingyot Klai-On
Ramkhamhaeng Hospital plc
Author Profile
Vipa Thanachartwet
Mahidol University Rajvithi Campus
Author Profile
Sirote Khunapornphairote
Ramkhamhaeng Hospital plc
Author Profile
Supat Chamnanchanunt
Mahidol University Rajvithi Campus
Author Profile
Theerapat Racharak
Ramkhamhaeng Hospital plc
Author Profile
Wannada Laisuan
Mahidol University Faculty of Medicine Ramathibodi Hospital
Author Profile
Duangjai Sahassananda
Mahidol University Rajvithi Campus
Author Profile
Samlee Hapunna
Ramkhamhaeng Hospital plc
Author Profile
Somjit Jinapuk
Ramkhamhaeng Hospital plc
Author Profile
Suthee Leelasetakul
Ramkhamhaeng Hospital plc
Author Profile
Varunee Desakorn
Mahidol University Rajvithi Campus
Author Profile

Abstract

Three patients with COVID-19 pneumonia received treatment with hydroxychloroquine combined with lopinavir plus ritonavir and favipiravir. Two patients early diagnosed with COVID-19 pneumonia received tocilizumab at severe pneumonia diagnosed and survived. The third patient was late diagnosed and received tocilizumab when the disease progressed to ARDS, and passed away.

Peer review status:ACCEPTED

17 Jul 2020Submitted to Clinical Case Reports
20 Jul 2020Submission Checks Completed
20 Jul 2020Assigned to Editor
23 Jul 2020Reviewer(s) Assigned
30 Jul 2020Review(s) Completed, Editorial Evaluation Pending
04 Sep 20201st Revision Received
05 Sep 2020Submission Checks Completed
05 Sep 2020Assigned to Editor
05 Sep 2020Review(s) Completed, Editorial Evaluation Pending
08 Sep 2020Editorial Decision: Accept